Cingulate Inc
CING7.700USD
+1.210+18.64%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
46.03MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Cingulate Inc Unternehmen
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Cingulate Inc Informationen
BörsenkürzelCING
Name des UnternehmensCingulate Inc
IPO-datumOct 07, 2021
CEOCallahan (Jennifer L)
Anzahl der mitarbeiter13
WertpapierartOrdinary Share
GeschäftsjahresendeOct 07
Addresse1901 W. 47Th Place
StadtKANSAS CITY
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl66205
Telefon19139422300
Websitehttps://www.cingulate.com/
BörsenkürzelCING
IPO-datumOct 07, 2021
CEOCallahan (Jennifer L)
Führungskräfte von Cingulate Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Fri, Feb 6
Aktualisiert: Fri, Feb 6
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
2.06%
Werth Family Investment Associates LLC
1.34%
Kestra Advisory Services, LLC
1.28%
Geode Capital Management, L.L.C.
0.58%
UBS Financial Services, Inc.
0.38%
Andere
94.37%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
2.06%
Werth Family Investment Associates LLC
1.34%
Kestra Advisory Services, LLC
1.28%
Geode Capital Management, L.L.C.
0.58%
UBS Financial Services, Inc.
0.38%
Andere
94.37%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
4.45%
Corporation
1.38%
Investment Advisor/Hedge Fund
0.69%
Research Firm
0.25%
Andere
93.23%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
33
295.34K
5.70%
--
2025Q3
44
295.34K
6.89%
+113.00
2025Q2
41
295.23K
5.36%
+158.62K
2025Q1
38
136.60K
4.92%
-48.84K
2024Q4
38
91.23K
3.95%
+40.70K
2024Q3
38
50.54K
3.01%
-30.23K
2024Q2
36
80.24K
1.97%
+46.92K
2024Q1
36
33.32K
1.85%
+25.60K
2023Q4
33
318.00
10.05%
-5.36K
2023Q3
30
5.68K
6.07%
+3.89K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
73.80K
1.03%
+38.42K
+108.60%
Sep 30, 2025
Werth Family Investment Associates LLC
97.99K
1.36%
--
--
Aug 01, 2025
Kestra Advisory Services, LLC
94.02K
1.31%
+94.02K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
42.41K
0.59%
+10.25K
+31.88%
Sep 30, 2025
UBS Financial Services, Inc.
1.30K
0.02%
-11.35K
-89.74%
Sep 30, 2025
LPL Financial LLC
20.25K
0.28%
+8.07K
+66.32%
Sep 30, 2025
Virtu Americas LLC
10.77K
0.15%
-2.58K
-19.32%
Sep 30, 2025
Quantum Private Wealth, LLC
24.00K
0.33%
+14.00K
+140.00%
Sep 30, 2025
Northern Trust Investments, Inc.
8.00K
0.11%
+8.00K
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
